Compare Schlumberger NV (SLB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Viatris Inc — how do they compare? Schlumberger NV trades at $52.67 (market cap $79.67B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Schlumberger NV is far larger — about 4.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| SLB | VTRS | |
|---|---|---|
Market Cap | $79.67B | $18.69B |
Sector | Energy | Health |
52-Week High | $58.01 | $17.86 |
52-Week Low | $31.72 | $9.49 |
Enterprise Value | $88.40B | $30.80B |
Dividend Yield | 2.2% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB (NYSE: SLB) trades at $53.02, down 0.34% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.55 exceeding expectations. Revenue trends show stability at $35.7B in 2025, though net income margin declined to 8.53%. Analyst consensus remains overwhelmingly positive with 85% buy ratings and a $63 price target representing 19% upside potential.
SLB's outlook is supported by robust digital and production systems growth, though Middle East exposure and net debt pose near-term risks. The stock offers 2.25% dividend yield with recent quarterly payouts of $0.30. While technical indicators show some overbought conditions with RSI at 74, fundamental strength and Wall Street optimism suggest continued upside potential, balanced by geopolitical and margin compression risks.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
